| Candidate ID: | R1322 |
| Source ID: | DB10770 |
| Source Type: | approved |
| Compound Type: |
biotech
|
| Compound Name: |
Foreskin fibroblast (neonatal)
|
| Synonyms: |
foreskin fibroblast, neonatal
|
| Molecular Formula: |
--
|
| SMILES: |
--
|
| DrugBank Description: |
Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types .
Also known as Dermagraft, this device is a cryopreserved human fibroblast-derived dermal substitute. Composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold, it effectively supports wound healing .
Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. The device is available for commercial distribution in Australia, Canada, Finland, France, Hong Kong, Ireland, The Netherlands, New Zealand, Singapore, and The United Kingdom .
The impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation. If wound closure is achieved, it is likely to delay the need for surgical intervention and provide other benefits such as improvements in productivity, mental outlook, social interactions, and time at work, in addition to decreased mortality .
Interestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells . Dermagraft has been combined with to create a drug beneficial to patients with open burn wounds .
|
| CAS Number: |
--
|
| Molecular Weight: |
|
| DrugBank Indication: |
This device is indicated for use for the treatment of full-thickness, diabetic foot ulcers greater than six weeks duration which extends through the dermis, but without tendon, muscle, joint capsule or bone exposure. This drug should be used in conjunction with standard wound care regimens and in patients with an adequate blood supply to the involved foot .
|
| DrugBank Pharmacology: |
This physiologically active dermal substitute is a scaffold upon which tissue can grow, allowing for effective healing of wounds .
Dermagraft is made from human fibroblast cells obtained from newborn foreskin tissue. During the manufacturing process, the human fibroblasts are placed onto a bioabsorbable polyglactin mesh scaffold. The fibroblasts grow to fill the interstices of this scaffold and secrete human dermal collagen, matrix proteins, and growth factors, as well as cytokines. This creates a three-dimensional human dermal substitute containing active, living cells. Dermagraft does not contain macrophages, lymphocytes, blood vessels, or hair follicles .
Among other cytokines, this device induces the production of interleukin 6 (IL-6). This gene encodes a cytokine that functions in inflammation and the maturation of B type immune cells. In addition the above, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is mainly produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The function this gene is involved in a wide variety of inflammation-associated disease states, including susceptibility to diabetes mellitus and systemic juvenile rheumatoid arthritis .
|
| DrugBank MoA: |
Dermagraft is a cryopreserved, human fibroblast-derived dermal substitute that contains fibroblasts, extracellular matrix, and a bioabsorbable polyglactin mesh scaffold . The fibroblasts are obtained from human newborn foreskin tissue. The fibroblasts are then placed on a scaffold and progress to proliferate and produce human dermal collagen, matrix proteins, growth factors, and cytokines. The above steps create a three-dimensional human dermal substitute with active human cells. Dermagraft does not contain macrophages, lymphocytes, blood vessels, nor hair follicles. It is available frozen as a single sheet (2 by 3 inches) for a single application .
|
| Targets: |
Interleukin-6 agonist; Vascular endothelial growth factor receptor 1 agonist; Interleukin-1 receptor type 1 agonist; TGF-beta receptor type-2 agonist; Fibroblast growth factor 1 agonist; Interferon gamma agonist; Fibroblast growth factor receptor 2 agonist; Granulocyte-macrophage colony-stimulating factor receptor subunit alpha agonist; Platelet-derived growth factor receptor beta agonist; Transforming growth factor beta-1 agonist; Tumor necrosis factor agonist
|
| Inclusion Criteria: |
Target associated
|
